Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Review
a r t i c l e
i n f o
Article history:
Received 26 August 2010
Received in revised form 5 January 2011
Accepted 7 January 2011
Available online 15 January 2011
Keywords:
Polycystic kidney disease
Apoptosis
Cell Cycle
Caspases
a b s t r a c t
Apoptosis is the process of programmed cell death. It is a ubiquitous, controlled process consuming cellular
energy and designed to avoid cytokine release despite activation of local immune cells, which clear the cell
fragments. The process occurs during organ development and in maintenance of homeostasis. Abnormalities
in any step of the apoptotic process are associated with autoimmune diseases and malignancies. Polycystic
kidney disease (PKD) is the most common inherited kidney disease leading to end-stage renal disease (ESRD).
Cyst formation requires multiple mechanisms and apoptosis is considered one of them. Abnormalities in
apoptotic processes have been described in various murine and rodent models of PKD as well as in human
PKD kidneys. The purpose of this review is to outline the role of apoptosis in progression of PKD as well as
to describe the mechanisms involved. This article is part of a Special Issue entitled: Polycystic Kidney
Disease.
2011 Elsevier B.V. All rights reserved.
1. Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the
most common life threatening hereditary disease in the USA [1]. It
affects about 1:500 people. Approximately 50% of people with ADPKD
develop renal failure. ADPKD accounts for about 510% of end-stage
renal disease requiring dialysis and renal transplantation [1]. PKD1
encodes polycystin-1 and mutations in this gene account for about
85% of cases of ADPKD, while mutations in PKD2 encoding polycystin2 are responsible for 1015%. Autosomal recessive polycystic kidney
disease (ARPKD) affects 1 in 20,000 live births and is an important
cause of renal and liver-related morbidity and mortality in neonates
and infants [2,3]. This disease is caused by mutations in the polycystic
kidney and hepatic disease gene 1 (PKHD1) which encodes brocystin/polyductin (FC1), a 500-kDa type I membrane protein expressed
in the primary cilium and plasma membrane of renal and bile duct
epithelial cells, as well as in the extrahepatic biliary duct [4,5].
Abnormalities of both cyst-lining epithelium and the noncystic
tubular epithelium contribute to cyst formation in the kidney and
are key to the disease progression.
The following molecular abnormalities of the tubular epithelium
lining the cysts have been extensively described: (1) abnormal uid
secretion, (2) abnormalities of cellmatrix interactions, (3) altera-
Table 1
Caspases are divided into two sub-groups: caspases involved in the inammatory
process and those involved in the apoptotic process. The apoptotic caspases are further
subdivided into initiating and executing caspases. Initiating caspases are activated by
either external stimuli via activation of extracellular death receptors or by loss of the
mitochondrial outer membrane potential leading to release of cytochrome c into the
cytosol.
Inammatory Apoptotic Initiating apoptotic Executing apoptotic
caspase
caspase
caspase
caspase
Caspase-1
Caspase-2
Caspase-3
Caspase-4
Caspase-5
Caspase-6
Caspase-7
Caspase-8
Caspase-9
Caspase-10
Caspase-11
Caspase-12
1273
1274
Fig. 1. Intracellular pathways of apoptosis. External apoptotic stimuli (extrinsic) lead to activation of caspase-8, while mitochondrial damage (intrinsic) leads to activation of
caspase-9. Both pathways converge to activation of executing caspases. Activation of executing caspases is considered the point of no return. Both apoptotic pathways can be
inhibited by IAPs. The intrinsic pathway can also be inhibited by antiapoptotic members of the Bcl-2 family of proteins and activation of caspase-8 in the extrinsic pathway can be
inhibited by c-FLIP.
being the primary cause of the decline in renal function and the other,
claiming that inducing apoptosis slows down disease progression
[54]. Clearly, both epithelial cell apoptosis and proliferation are
dysregulated in ADPKD and may represent a general mechanism for
cyst growth and tissue remodeling [1,44]. By applying simple logic, it
is evident that apoptosis per se cannot be the main culprit for PKD,
because polycystic kidneys are massively enlarged and if apoptosis
were to be the predominant feature, it would be expected that the
kidneys would eventually involute, such as is the case in the majority
of congenital dysplastic kidneys [55]. It seems that it is an imbalance
between proapoptotic and pro-proliferative factors, rather than the
absolute expression levels that play a critical role in the development
of cystic kidney disease [56]. This imbalance leads to aberrant cell
cycle progression in a similar fashion to cancer, such that PKD has
been labeled neoplasia in disguise [57]. Cancers are generally
characterized by suppression of apoptosis and the goal of cancer
therapy is to induce apoptosis in malignant cells [58]. In the Bcl-2
transgenic mouse model, Bcl-2 was retrovirally introduced into the
bone marrow of wild-type mice or transgenic mice overexpressing
the c-myc oncogene (Em-myc) [59]. Bcl-2 cooperated with c-myc to
promote transformation of B cell precursors [60]. Although developmentally normal, the adult Bcl-2/ mouse displays thymus and
spleen involution, polycystic kidney disease, and hypopigmented hair
due to increased apoptosis. Mice decient in the proapoptotic Bcl-2
gene have hyperproliferation as well as apoptosis with renal cysts
[46,61]. Transgenic expression of human Bcl-2 in all organs except the
kidneys resulted in early death due to renal failure due to PKD in this
mouse model [62]. However, in an in vitro model of PKD, apoptosis
was shown to be causally linked to cyst formation [63]. Apoptosis was
essential for MadinDarby canine kidney (MDCK) cell cyst cavitation in
1275
Fig. 2. In situ hybridization using terminal transferase-mediated dUTP nick end-labeling (TUNEL) method in a kidney from a patient with early-stage ADPKD (B), normal agematched kidney (A), a fetal ARPKD kidney (F), and an age-matched fetal kidney (E). Note the lack of apoptosis in the normal adult kidney and the relative abundance in the
nephrogenic zone of the normal fetal kidney. Long arrows in (B) point on sporadic apoptotic cells in cyst-lining epithelia of small cysts and short arrows point on apoptosis in
epithelium of normal-appearing tubules (D) depict an area within a section from an end-stage ADPKD kidney (patient is on renal replacement therapy), demonstrating hyperplastic
cyst-lining epithelium, accompanied by extensive apoptosis.
Reprint from Goilav et al. Pediatr Nephrol 2008, with permission.
5. Caspase activation
Increased rates of apoptosis and increased caspase-3 activity have
been demonstrated in kidneys from ARPKD rodent models [81,82].
Apoptosis is localized primarily to the interstitium with little evidence
of cell death in cyst epithelium or noncystic tubules. A marked
1276
cycle [91]. Most genes encoding cyclins and CDKs are conserved
among all eukaryotes [92]. Cyclins form the regulatory subunits and
CDKs the catalytic subunits of an activated heterodimer. CDKs are
constitutively expressed in cells whereas cyclins are synthesized at
specic stages of the cell cycle, in response to various molecular
signals [93].
Two families of genes, the cip/kip family and the INK4a/ARF
(Inhibitor of Kinase 4/Alternative Reading Frame) encode CDK
inhibitors. These genes are considered to be tumor suppressors [94].
The cip/kip family includes the genes p21, p27, and p57. They halt cell
cycle in G1 phase and inactivate, cyclin-CDK complexes. p21 is
activated by p53. The INK4a/ARF family includes p16INK4a, which
binds to CDK4 and arrests the cell cycle in G1 phase, and p14arf, which
prevents p53 degradation.
Abnormal cell cycle regulation has been suggested to contribute to
PKD. Polycystin-1 increases expression of p21, and p21 is decreased in
human and a rat model of PKD [95,96]. These ndings are consistent
with the observed augmentation of both cell proliferation and
apoptosis in this disease.
9. Therapeutic interventions implicating apoptotic pathways
9.1. Mammalian target of rapamycin (mTOR)
The mammalian target of rapamycin (mTOR) pathway is an
evolutionarily conserved pathway that transmits cell growth and
survival signals in cells. It senses the availability of nutrients and
growth factors in the environment and responds by signaling for
cell growth and division [97]. The mTOR pathway has become of
interest in the pathophysiology of PKD because it also integrates
signals from growth factors (including EGFR) and G-protein
coupled receptors (which generate cAMP) [98,99]. Mutated TSC1
and TSC2 genes cause tuberous sclerosis, a disease in which renal
cystic lesions may accompany the more classical renal angiomyolipomas [100] and TSC1/2 mutations are associated with upregulate
mTOR signaling. The TSC2 and PKD1 genes lie adjacent to each other
on human chromosome 16p13.3 and the cytoplasmic tail of
polycystin-1 interacts with mTOR. This sparked the interest for a
possible mTOR activity in PKD. In a variety of animal models, as well
as in human ADPKD and ARPKD cyst-lining epithelia, expression of
phospho-mTOR and p70S6K is increased [101]. Indeed, in the
absence of polycystin-1, activation of mTOR results in increased cell
growth. Inhibition of the mTOR pathway reverses renal cystogenesis in PKD and has been associated with an increased rate in
apoptosis in vitro [102]. Rapamycin is an immunosuppressive drug
that inhibits mTOR and is used to prevent transplant rejection.
Rapamycin and a related drug everolimus were evaluated in the
Han:SPRD rat [103,104]. Inhibition of mTOR signicantly slows cyst
growth in this model. Other studies have tested the efcacy of
rapamycin in three non-orthologous mouse models of PKD,
Tg737orpk/orpk mice (mutation in the ciliary protein Polaris),
bpk mice, and kidney-specic BHD (gene mutated in patients with
BirtHoggDub syndrome) mutant mice [101,105]. These studies
also revealed signicant improvement in cyst size and azotemia
compared to control animals. In a retrospective study, Shillingford
examined a small group of patients who had undergone kidney
transplantation for ESRD due to ADPKD and retained their native
cystic kidneys [101]. In four patients who received rapamycin as
part of their post-transplant immunosuppression, the volume of the
native cystic kidneys was reduced by 24% compared to 8.6% in three
patients treated with other immunosuppressants. The change in
kidney size was signicantly different between the rapamycin and
non-rapamycin groups. Another retrospective study by Qian demonstrated that rapamycin decreased the size and number of liver
cysts but failed to show a benet on kidney cysts [106]. Nonetheless, these results were encouraging enough to lead to prospective
1277
1278
[39] V.A. Fadok, D.L. Bratton, S.C. Frasch, M.L. Warner, P.M. Henson, The role of
phosphatidylserine in recognition of apoptotic cells by phagocytes, Cell Death
Differ. 5 (1998) 551562.
[40] G. Koopman, C.P.M. Reutenlingsperger, G.A.M. Kuijten, R.M.J. Keehnen, S.T.
Pals, M.H.J. van Oers, Annexin V for ow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis, Blood 84 (1994)
14151420.
[41] G. Van Loo, X. Saelens, M. van Gurp, M. MacFarlane, S.J. Martin, P. Vandenabeele,
The role of mitochondrial factors in apoptosis: a Russian roulette with more than
one bullet, Cell Death Differ. 10 (2002) 10311042.
[42] M. Poot, R.H. Pierce, Detection of changes in mitochondrial function during
apoptosis by simultaneous staining with multiple uorescent dyes and
correlated multiparameter ow cytometry, Cytometry 35 (1999) 311317.
[43] N.S. Murcia, W.E. Sweeney Jr., E.D. Avner, New insights into the molecular
pathophysiology of polycystic kidney disease, Kidney Int. 55 (1999)
11871197.
[44] J. Lanoix, V. D'Agati, M. Szabolcs, M. Trudel, Dysregulation of cellular
proliferation and apoptosis mediates human autosomal dominant polycystic
kidney disease (ADPKD), Oncogene 13 (1996) 11531160.
[45] M. Trudel, V. D'Agati, F. Constantini, c-myc as an inducer of polycystic kidney
disease in transgenic mice, Kidney Int. 39 (1991) 665671.
[46] D.J. Veis, C.M. Sorenson, J.R. Shutter, S.J. Korsmeyer, Bcl-2-decient mice
demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair, Cell 75 (1993) 229240.
[47] M. Trudel, J. Lanoix, L. Barisoni, M.J. Blouin, M. Desforges, C. L'Italien, V.D. D'Agati,
C-MYC-induced apoptosis in polycystic kidney disease is Bcl-2 and p53
independent, J. Exp. Med. 186 (1997) 18731884.
[48] M. Trudel, L. Barisoni, J. Lanoix, V. D'Agati, Polycystic kidney disease in SBM
transgenic mice: role of c-myc in disease induction and progression, Am. J.
Pathol. 152 (1998) 219229.
[49] K. Schfer, N. Gretz, M. Bader, I. Oberbumer, K.U. Eckardt, W. Kriz, S. Bachmann,
Characterization of the Han:SPRD rat model for hereditary polycystic kidney
disease, Kidney Int. 46 (1994) 134152.
[50] J. Kaspareit-Rittinghausen, F. Deerberg, A. Wcislo, Hereditary polycystic kidney
disease: adult polycystic kidney disease associated with renal hypertension,
renal osteodystrophy, and uremic enteritis in SPRD rats, Am. J. Pathol. 139
(1991) 693696.
[51] B.D. Cowley, S. Gudapaty, A.L. Kraybill, B.D. Barash, M.A. Harding, J.P. Clavet, V.H.
Gattone, Autosomal dominant polycystic kidney disease in the rat, Kidney Int. 43
(1993) 522534.
[52] K. Schfer, M. Bader, N. Gretz, I. Oberbumer, S. Bachmann, Focal overexpression
of collagen IV characterizes the initiation of epithelial changes in polycystic
kidney disease, Exp. Nephrol. 2 (1994) 190195.
[53] M.R. Ogborn, N. Bankovic-Calic, C. Shoesmith, R. Buist, J. Peeling, Soy protein
modication of rat polycystic kidney disease, Am. J. Physiol. 274 (1998)
F541F549.
[54] X.J. Zhou, G. Kukes, Pathogenesis of autosomal dominant polycystic kidney
disease: Role of apoptosis, Diagn. Mol. Pathol. 7 (1998) 6568.
[55] D.S. Hains, C.M. Bates, S. Ingraham, A.L. Schwaderer, Management and etiology of
the unilateral multicystic dysplastic kidney: a review, Pediatr. Nephrol. 24
(2009) 233241.
[56] T. Ecder, V.Y. Melnikov, M. Stanley, D. Korular, M.S. Lucia, R.W. Schrier, C.L.
Edelstein, Caspases, Bcl-2 proteins and apoptosis in autosomal dominant
polycystic kidney disease, Kidney Int. 61 (2002) 12201230.
[57] J.J. Grantham, Polycystic kidney disease: neoplasia in disguise, Am. J. Kidney Dis.
15 (1990) 110116.
[58] G.I. Evan, K.H. Vousden, Proliferation, cell cycle and apoptosis in cancer, Nature
411 (2001) 342348.
[59] T.J. McDonnell, N. Deane, F.M. Platt, G. Nunez, U. Jaeger, J.P. McKearn, S.J.
Korsmeyer, bcl-2-immunoglobulin transgenic mice demonstrate extended B cell
survival and follicular lymphoproliferation, Cell 7 (1989) 7988.
[60] D.L. Vaux, S. Cory, J.M. Adams, Bcl-2 gene promotes haemopoietic cell survival
and cooperates with c-myc to immortalize pre-B cells, Nature 335 (1988)
440442.
[61] C.M. Sorenson, B.J. Padanilam, M.R. Hammerman, Abnormal postpartum renal
development and cystogenesis in the bcl-2 (-/-) mouse, Am. J. Physiol. 271
(1996) F184F193.
[62] L.M. Fedorov, C. Schmittwolf, K. Amann, W.H. Thomas, A.M. Mller, H. Schubert,
J. Domen, B. Kneitz, Renal failure causes early death of bcl-2 decient mice,
Mech. Ageing Dev. 127 (2006) 600609.
[63] H.H. Lin, T.P. Yang, S.T. Jiang, H.Y. Yang, M.J. Tang, Bcl-2 over-expression prevents
apoptosis-induced MadinDarby canine kidney simple epithelial cyst formation,
Kidney Int. 55 (1999) 168178.
[64] C.L. Freeman, J.H. Harding, D. Quigley, P.M. Rodger, Structural control of
crystal nuclei by an eggshell protein, Angew. Chem. Int. Ed. 49 (2010)
51355137.
[65] P.J. Winyard, J. Nauta, D.S. Lirenman, P. Hardman, V.R. Sams, R.A. Risdon, A.S.
Woolf, Deregulation of cell survival in cystic and dysplastic renal development,
Kidney Int. 49 (1996) 135146.
[66] D.J. Lager, Q. Qian, R.J. Bengal, M. Ishibashi, V.E. Torres, The pck rat: a new model
that resembles human autosomal dominant polycystic kidney and liver disease,
Kidney Int. 59 (2001) 126136.
[67] C.L. Edelstein, What is the role of tubular epithelial cell apoptosis in polycystic
kidney disease (PKD)? Cell Cycle 4 (2005) e141e145.
[68] Y. Tao, J. Kim, S. Faubel, J.C. Wu, S.A. Falk, R.W. Schrier, C.L. Edelstein, Caspase
inhibition reduces tubular apoptosis and proliferation and slows disease
[69]
[70]
[71]
[72]
[73]
[74]
[75]
[76]
[77]
[78]
[79]
[80]
[81]
[82]
[83]
[84]
[85]
[86]
[87]
[88]
[89]
[90]
[91]
[92]
[93]
[94]
progression in polycystic kidney disease, Proc. Natl Acad. Sci. USA 102 (2005)
69546959.
M. Moser, A. Pscherer, C. Roth, J. Becker, G. Mucher, K. Zerres, C. Dixkens, J. Weis,
L. Guay-Woodford, R. Buettner, R. Fassler, Enhanced apoptotic cell death of renal
epithelial cells in mice lacking transcription factor AP-2beta, Genes Dev. 11
(1997) 19381948.
A. Boletta, F. Qian, L.F. Onuchic, A.K. Bhunia, B. Phakdeekitcharoen, K. Hanaoka,
W. Guggino, L. Monaco, G.G. Germino, Polycystin-1, the gene product of PKD1,
induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells,
Mol. Cell 6 (2000) 12671273.
K. Nakayama, K. Nakayama, I. Negishi, K. Kuida, H. Sawa, D.Y. Loh, Targeted
disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic
kidney disease, and lymphocytopenia, Proc. Natl Acad. Sci. USA 91 (1994)
37003704.
S. Kamada, A. Shimono, Y. Shinto, T. Tsujimura, T. Takahashi, T. Noda, Y.
Kitamura, H. Kondoh, Y. Tsujimoto, Bcl-2 deciency in mice leads to pleiotropic
abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic
kidney, hair hypopigmentation, and distorted small intestine, Cancer Res. 55
(1995) 354359.
C. Wodarczyk, G. Distefano, I. Rowe, M. Gaetani, B. Bricoli, M. Muorah, A.
Spitaleri, V. Mannella, P. Ricchiuto, M. Pema, M. Castelli, A.E. Casanova, L. Mollica,
M. Banzi, M. Boca, C. Antignac, S. Saunier, G. Musco, A. Boletta, Nephrocystin-1
forms a complex with polycystin-1 via a polyproline motif/sh3 domain
interaction and regulates the apoptotic response in mammals, PLoS ONE 5
(2010) e12719.
W. Yu, T. Kong, S. Beaudry, M. Tran, H. Negoro, V. Yanamadala, B.M. Denker,
Polycystin-1 protein level determines activity of the Galpha12/JNK apoptosis
pathway, J. Biol. Chem. 285 (2010) 1024310251.
W. Yu, B.J. Ritchie, X. Su, J. Zhou, T.E. Meigs, B.M. Denker, Identication of
polycystin-1 and G12 binding regions necessary for regulation of apoptosis,
Cell. Signal. 23 (2011) 213221.
A. Stroope, B. Radtke, B. Huang, T. Masyuk, V. Torres, E. Ritman, N. LaRusso,
Hepato-renal pathology in pkd2ws25/ mice, an animal model of autosomal
dominant polycystic kidney disease, Am. J. Pathol. 176 (2010) 12821291.
W. Mai, D. Chen, T. Ding, I. Kim, S. Park, S.Y. Cho, J.S. Chu, D. Liang, N.
Wang, D. Wu, S. Li, P. Zhao, R. Zent, G. Wu, Inhibition of Pkhd1 impairs
tubulomorphogenesis of cultured IMCD cells, Mol. Biol. Cell 16 (2005)
43984409.
H.M. Shen, V. Tergaonkar, NFkappaB signaling in carcinogenesis and as a
potential molecular target for cancer therapy, Apoptosis 14 (2009) 348363.
S. Grimm, M.K. Bauer, P.A. Baeuerle, K. Schulze-Osthoff, Bcl-2 down-regulates
the activity of transcription factor NF-kappaB induced upon apoptosis, J. Cell Biol.
134 (1996) 1323.
A. Mangolini, M. Bogo, C. Durante, M. Borgatti, R. Gambari, P.C. Harris, R. Rizzuto,
P. Pinton, G. Aguiari, L. del Senno, NF-kappaB activation is required for apoptosis
in brocystin/polyductin-depleted kidney epithelial cells, Apoptosis 15 (2010)
94104.
D.D. Woo, S.Y. Miao, J.C. Pelayo, A.S. Woolf, Taxol inhibits progression of
congenital polycystic kidney disease, Nature 368 (1994) 750753.
S.M. Ali, V.Y. Wong, K. Kikly, T.A. Fredrickson, P.M. Keller, W.E. DeWolf Jr., D. Lee,
D.P. Brooks, Apoptosis in polycystic kidney disease: involvement of caspases,
Am. J. Physiol. Regul. Integr. Comp. Physiol. 278 (2000) R763R769.
Y. Tao, J. Kim, M. Stanley, Z. He, S. Faubel, R.W. Schrier, C.L. Edelstein, Pathways of
caspase-mediated apoptosis in autosomal dominant polycystic kidney disease
(ADPKD), Kidney Int. 67 (2004) 909919.
Y. Tao, I. Zafar, J. Kim, R.W. Schrier, C.L. Edelstein, Caspase-3 gene deletion
prolongs survival in polycystic kidney disease, J. Am. Soc. Nephrol. 19 (2008)
749755.
B. Goilav, P.D. Wilson, Localization and timing of c-FLIP expression in human
autosomal dominant polycystic kidney disease: a mirror image of caspase8 expression, Oral abstract presentation at Pediatric Academic Societies'
Meeting, (2008) Hawaii, HI, 2008.
B.D. Cowley Jr., L.J. Chadwick, J.J. Grantham, J.P. Calvet, Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease, Proc. Natl
Acad. Sci. USA 84 (1987) 83948398.
B.D. Cowley Jr., L.J. Chadwick, J.J. Grantham, J.P. Calvet, Elevated proto-oncogene
expression in polycystic kidneys of the C57BL/6J (cpk) mouse, J. Am. Soc.
Nephrol. 1 (1991) 10481053.
M. Trudel, V.D. Agati, F. Costantini, C-myc as an inducer of polycystic kidney
disease in transgenic mice, Kidney Int. 39 (1991) 665671.
J.L. Ricker, J.E. Mata, P.L. Iversen, V.H. Gattone, c-myc antisense oligonucleotide
treatment ameliorates murine ARPKD, Kidney Int. 61 (2002) 125131.
M.S. Soengas, R.M. Alarcon, H. Yoshida, A.J. Giaccia, R. Hakem, T.W. Mak, S.W.
Lowe, Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition,
Science 284 (1999) 156159.
E.A. Nigg, Cyclin-dependent protein kinases: key regulators of the eukaryotic cell
cycle, Bioessays 17 (1995) 471480.
P.T. Spellman, G. Sherlock, M.Q. Zhang, V.R. Iyer, K. Anders, M.B. Eisen, P.O.
Brown, D. Botstein, B. Futcher, Comprehensive identication of cell cycleregulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization, Mol. Biol. Cell 9 (1998) 32733297.
R. Suryadinata, M. Sadowski, B. Sarcevic, Control of cell cycle progression by
phosphorylation of cyclin-dependent kinase (CDK) substrates, Biosci. Rep. 30
(2010) 243255.
R.P. Fisher, Coming full circle: cyclin-dependent kinasese as anti-cancer drug
targets, Subcell. Biochem. 50 (2010) 115.
1279
[95] A.K. Bhunia, K. Piontek, A. Boletta, L. Liu, F. Qian, P.N. Xu, F.J. Germino, G.G.
Germino, PKD1 induces p21(waf1) and regulation of the cell cycle via direct
activation of the JAK-STAT signaling pathway in a process requiring PKD2, Cell
109 (2002) 157168.
[96] J.Y. Park, W.E. Schutzer, J.N. Lindsley, S.P. Bagby, T.T. Oyama, S. Anderson, R.H.
Weiss, p21 is decreased in polycystic kidney disease and leads to increased
epithelial cell cycle progression: roscovitine augments p21 levels, BMC Nephrol.
8 (2007) 1222.
[97] D.C. Fingar, J. Blenis, Target of rapamycin (TOR): an integrator of nutrient and
growth factor signals and coordinator of cell growth and cell cycle progression,
Oncogene 23 (2004) 31513171.
[98] S. Wullschleger, R. Loewith, M.N. Hall, TOR signaling in growth and metabolism,
Cell 124 (2006) 471484.
[99] C.L. Edelstein, Mammalian target of rapamycin and caspase inhibitors in
polycystic kidney disease, Clin. J. Am. Soc. Nephrol. 3 (2008) 12191226.
[100] S.L. Habib, Tuberous sclerosis complex and DNA repair, Adv. Exp. Med. Biol. 685
(2010) 8494.
[101] J.M. Shillingford, N.S. Murcia, C.H. Larson, S.H. Low, R. Hedgepeth, N. Brown, C.A.
Flask, A.C. Novick, D.A. Goldfarb, A. Kramer-Zucker, G. Walz, K.B. Piontek, G.G.
Germino, T. Weimbs, The mTOR pathway is regulated by polycystin-1, and its
inhibition reverses renal cystogenesis in polycystic kidney disease, Proc. Natl
Acad. Sci. USA 103 (2006) 54665471.
[102] J.M. Shillingford, K.B. Piontek, G.G. Germino, T. Weimbs, Rapamycin ameliorates
PKD resulting from conditional inactivation of Pkd1, J. Am. Soc. Nephrol. 3
(2010) 489497.
[103] P.R. Wahl, A.L. Serra, M. Le Hir, K.D. Molle, M.N. Hall, R.P. Wuthrich, Inhibition of
mTOR with sirolimus slows disease progression in Han:SPRD rats with
autosomal dominant polycystic kidney disease (ADPKD), Nephrol. Dial.
Transplant. 21 (2006) 598604.
[104] M. Wu, P.R. Wahl, M. Le Hir, Y. Wackerle-Men, R.P. Wuthrich, A.L. Serra,
Everolimus retards cyst growth and preserves kidney function in a rodent
model for polycystic kidney disease, Kidney Blood Press. Res. 30 (2007)
253259.
[105] M. Baba, M. Furihata, S.B. Hong, L. Tessarollo, D.C. Haines, E. Southon, V.
Patel, P. Igarashi, W.G. Alvord, R. Leighty, M. Yao, M. Bernardo, L. Ileva,
P. Choyke, M.B. Warren, B. Zbar, W.M. Linehan, L.S. Schmidt, Kidney-targeted
BirtHoggDube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR
activation, cell hyperproliferation, and polycystic kidneys, J. Natl Cancer Inst.
100 (2008) 140154.
[106] Q. Qian, H. Du, B.F. King, S. Kumar, P.G. Dean, F.G. Cosio, V.E. Torres, Sirolimus
reduces polycystic liver volume in ADPKD patients, J. Am. Soc. Nephrol. 19
(2008) 631638.
[107] G. Walz, K. Budde, M. Mannaa, J. Nrnberger, C. Wanner, C. Sommerer, U.
Kunzendorf, B. Banas, W.H. Hrl, N. Obermller, W. Arns, H. Pavenstdt, J.
Gaedeke, M. Bchert, C. May, H. Gschaidmeier, S. Kramer, K.U. Eckardt,
Everolimus in patients with autosomal dominant polycystic kidney disease, N.
Engl. J. Med. 363 (2010) 830840.
[108] A.L. Serra, D. Poster, A.D. Kistler, F. Krauer, S. Raina, J. Young, K.M. Rentsch, K.S.
Spanaus, O. Senn, P. Kristanto, H. Scheffel, D. Weishaupt, R.P. Wthrich, Sirolimus
and kidney growth in autosomal dominant polycystic kidney disease, N. Engl. J.
Med. 363 (2010) 820829.
[109] R.H. Weiss, p21Waf1/Cip1 as a therapeutic target in breast and other cancers,
Cancer Cell 4 (2003) 425429.
[110] M. Asada, T. Yamada, H. Ichijo, D. Delia, K. Miyazono, K. Fukumuro, S. Mizutani,
Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic
differentiation, EMBO J. 18 (1999) 12231234.
[111] Y. Fan, A.D. Borowsky, R.H. Weiss, An antisense oligodeoxynucleotide to p21
(Waf1/ Cip1) causes apoptosis in human breast cancer cells, Mol. Cancer Ther. 2
(2003) 773782.
[112] R.R. Sharma, T.S. Ravikumar, D. Raimo, W.L. Yang, Induction of p21(WAF1)
expression protects HT29 colon cancer cells from apoptosis induced by
cryoinjury, Ann. Surg. Oncol. 12 (2005) 743752.
[113] J.Y. Park, S.H. Park, R.H. Weiss, Disparate effects of roscovitine on renal tubular
epithelial cell apoptosis and senescence: implications for autosomal dominant
polycystic kidney disease, Am. J. Nephrol. 29 (2009) 509515.
[114] Z. Han, W. Wei, S. Dunaway, J.W. Darnowski, P. Calabresi, J. Sedivy, E.A.
Hendrickson, K.V. Balan, P. Pantazis, J.H. Wyche, Role of p21 in apoptosis and
senescence of human colon cancer cells treated with camptothecin, J. Biol. Chem.
277 (2002) 1715417160.
[115] U. Herbig, W.A. Jobling, B.P. Chen, D.J. Chen, J.M. Sedivy, Telomere shortening
triggers senescence of human cells through a pathway involving ATM, p53, and
p21(CIP1), but not p16(INK4a), Mol. Cell 14 (2004) 501513.
[116] T. Van Nguyen, N. Puebla-Osorio, H. Pang, M.E. Dujka, C. Zhu, DNA damageinduced cellular senescence is sufcient to suppress tumorigenesis: a mouse
model, J. Exp. Med. 204 (2007) 14531461.
[117] J.P. Brown, W. Wei, J.M. Sedivy, Bypass of senescence after disruption of
p21CIP1/WAF1 gene in normal diploid human broblasts, Science 277 (1997)
831834.
[118] G.P. Dimri, X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E.E. Medrano, M.
Linskens, I. Rubelj, O. Pereira-Smith, A biomarker that identies senescent
human cells in culture and in aging skin in vivo, Proc. Natl Acad. Sci. USA 92
(1995) 93639367.
[119] Z. Feng, H. Zhang, A.J. Levine, S. Jin, The coordinate regulation of the p53 and
mTOR pathways in cells, Proc. Natl Acad. Sci. 102 (2005) 82048209.
[120] V.E. Torres, Apoptosis in cystogenesis: hands on or hands off? Kidney Int. 55
(1999) 334335.
1280
[124] M.R. Ogborn, S. Sareen, Transforming growth factor alpha and epidermal growth
factor expression in experimental murine polycystic kidney disease, Pediatr.
Nephrol. 10 (1996) 181184.
[125] K.D. Liu, P.R. Brakeman, Renal repair and recovery, Crit. Care Med. 36 (2008)
S187S192.
[126] J.P. Calvet, Injury and development in polycystic kidney disease, Curr. Opin.
Nephrol. Hypertens. 3 (1994) 340348.
[127] C.S. Chen, H. Mrksich, S. Huang, G.M. Whitesides, D.E. Ingber, Geometric control
of cell life and death, Science 276 (1997) 14251429.